Platelet Membrane–Coated Tenecteplase for Arterial Clots

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the thrombolytic effect of platelet membrane–coated tenecteplase (PM-TNK) on human arterial thrombi using ex vivo samples. It also explores how plasma from patients taking antiplatelet therapy might inhibit PM-TNK activity. The study involves collecting venous or arterial blood to assess thrombolysis and potential interactions with prior antiplatelet treatment. Eligible participants include adults with suspected coronary artery disease undergoing angiography or interventional procedures, as well as healthy volunteers, with specific inclusion and exclusion criteria to ensure safety and data integrity. Conducted at The First Affiliated Hospital with Nanjing Medical University, this work aims to inform potential future clinical applications of PM-TNK.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\-

For CAD patients:

Age 18-75 years old, body weight ≥45kg, regardless of gender; Patients with suspected coronary artery disease scheduled for coronary angiography or interventional therapy.

Take aspirin and ticagrelor maintenance dose ≥3 days, or loading dose of aspirin (300mg) and ticagrelor (180mg) ≥12 hours;

For healthy volunteer:

Age 18-75 years old, body weight ≥45kg, regardless of gender

Exclusion Criteria:

For CAD patients 1. Previous thrombolytic therapy with TNK; 2. Those who are enrolled in other clinical trials; 3. Those who were deemed ineligible by other investigators.

For healthy volunteer:

1\. Currently taking any medication that may affect platelet function, such as antiplatelet drugs or nonsteroidal anti-inflammatory drugs. 2. Individuals with blood disorders, active bleeding or a tendency to bleed, including platelet count \<100×10\^9/L, hemoglobin \<100g/L, or recent bleeding in the digestive system or urinary tract within one month. 3. Individuals with impaired liver or kidney function, including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels above the upper limit of normal reference range, and estimated glomerular filtration rate (eGFR) \<90 mL/min/1.73m\^2 (calculated based on the CKD-EPI equation). 4. Recent (within one month) severe trauma, surgery, or head injury. 5. Pregnant or lactating women. 6. Diabetes. 7. Smokers. 8. Those who are enrolled in other clinical trials; 9. Those who were deemed ineligible by other investigators.

Where it's running

• The First Affiliated Hospital with Nanjing Medical University
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Chunjian Li
• Email: lijay@njmu.edu.cn
• Phone: 86-13701465229

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating heart-related side effects of cancer immunotherapy

  This study is testing whether cancer immunotherapy treatments can cause heart problems in patients with certain types of cancer.

  Recruiting Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam, North Holland · NCT06519292

• Registry for Antithrombotic Treatments in Patients with Antiphospholipid Syndrome

  This study is testing different blood-thinning treatments in people with antiphospholipid syndrome who had an artery problem in the last year to see which ones are safest and most effective.

  Recruiting at 3 sites McMaster University · Buenos Aires, Buenos Aires F.D. and 2 other locations · NCT05646394

• Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma

  In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.

  Recruiting Phase 4 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07907211

• Chemotherapy sensitivity-guided Culmerciclib combo for HR+/HER2- breast cancer before surgery

  This trial tests whether adding Culmerciclib to chemotherapy before surgery can help people with HR+/HER2- breast cancer who don’t respond to initial TAC treatment.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07900516

• Off-clamp, sutureless robot-assisted partial nephrectomy vs conventional robot-assisted partial nephrectomy

  This trial tests whether removing a small kidney tumor without clamping the blood supply and without stitching the kidney bed preserves kidney function better than the standard robot-assisted surgery.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07888608

• Chidamide, Lenalidomide, and Rituximab as induction therapy for newly diagnosed elderly or unfit double-expressor DLBCL

  This trial tests whether the combo of chidamide, lenalidomide, and rituximab can help treat newly diagnosed double-expressor DLBCL in people who are elderly or not fit for standard chemotherapy.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07884708

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.